Smarter Oncology Drug Management for Cancer Care
How Avalon integrates genetic testing with oncology drug management to improve outcomes, reduce costs, and eliminate inefficiencies.
Avalon’s Approach
Avalon’s oncology drug management program streamlines prior authorizations, standardizes testing, and aligns results with guideline-based therapies.
- Automated test authorization workflows to minimize delays
- Broad-panel next-generation sequencing (NGS) adoption to improve diagnostic accuracy and lower costs
- Guideline-driven treatment protocols to ensure results are applied consistently to therapy planning.
This evidence-based approach eliminates waste, improves clinical decision-making, and aligns with payers’ cost and quality goals.
Economic Opportunity
Transitioning from outdated sequential testing to Next-Generation Sequencing (NGS) delivers measurable clinical and financial value.
- Broad-panel testing, despite a $1,200 initial cost, saved $8,500 PMPM over sequential approaches. For commercial members, this model saved over $125,000 per individual.
- Improving genetic testing for high-risk breast cancer patients by 30% could yield $165 PMPM savings.
Diagnostic-Guided Oncology Drug Management
An advanced oncology drug management program, anchored in genetic data and diagnostic values, can transform cancer care pathways. Key capabilities include:
Eliminate prior authorizations for genetic testing via pre-negotiated rates and defined protocols.
Ensure comprehensive and timely testing through liquid biopsies and streamlined test workflows.
Map genetic mutations to evidence-based therapies for higher treatment precision.
Reduce chemotherapy misuse by shifting to biomarker-driven prescribing.
Accelerate time for treatment, improving clinical outcomes.
Strategic Impact
By integrating a third-party lab value management partner, health payers can:
Maximize treatment accuracy
Reduce avoidable spend
Improve member satisfaction and quality ratings
Demonstrate measurable ROI
This approach delivers win-win outcomes for patients, providers, and payers — backed by rigorous evidence and clear economic value.
Cancer care deserves better.
It’s time to champion smarter drug management and ensure every patient receives the right treatment, at the right time, for the right cost. Partner with the pioneers in lab value management.